Co-Authors
This is a "connection" page, showing publications co-authored by David Montefiori and Kevin Saunders.
Connection Strength
1.507
-
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell. 2021 08 05; 184(16):4203-4219.e32.
Score: 0.238
-
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. 2021 06; 594(7864):553-559.
Score: 0.236
-
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. NPJ Vaccines. 2021 Apr 09; 6(1):50.
Score: 0.235
-
Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. Cell Rep. 2017 12 26; 21(13):3681-3690.
Score: 0.187
-
Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell Rep. 2017 02 28; 18(9):2175-2188.
Score: 0.177
-
Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell. 2021 05 27; 184(11):2955-2972.e25.
Score: 0.059
-
Cold sensitivity of the SARS-CoV-2 spike ectodomain. Nat Struct Mol Biol. 2021 02; 28(2):128-131.
Score: 0.058
-
Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018 06 04; 215(6):1571-1588.
Score: 0.048
-
HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. J Virol. 2017 11 01; 91(21).
Score: 0.046
-
HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site. PLoS One. 2017; 12(10):e0177863.
Score: 0.046
-
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nat Commun. 2017 06 08; 8:15711.
Score: 0.045
-
Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. Sci Transl Med. 2017 03 15; 9(381).
Score: 0.044
-
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Sci Transl Med. 2017 03 15; 9(381).
Score: 0.044
-
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog. 2017 02; 13(2):e1006182.
Score: 0.044